---
document_datetime: 2025-06-02 14:57:56
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/upstaza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: upstaza-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.3924223
conversion_datetime: 2025-12-25 06:15:14.76064
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Upstaza

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                          |
|----------------------|--------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0025               | 2nd annual re-assessment | 27/02/2025                          | 23/04/2025                                  | SmPC and PL                      | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Upstaza should be maintained. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/11004 /202406   | Periodic Safety Update EU Single assessment - eladocagene exuparvovec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/01/2025   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| II/0023/G             | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal | 12/12/2024   | n/a   |                                     |
| II/0022/G             | This was an application for a group of variations. B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation                                                                                                                                                                                     | 25/07/2024   | n/a   | Not applicable                      |
| PSUSA/11004 /202312   | Periodic Safety Update EU Single assessment - eladocagene exuparvovec                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/07/2024   | n/a   | PRAC Recommendation - maintenance   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0021   | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 30/05/2024   | n/a        |                       |                                                                                                                                                                                                                                                                                                                          |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0014/G | This was an application for a group of variations. Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update information on safety and efficacy, based on final results from studies NTUH- AADC-010 and NTUH-AADC-011. NTUH-AADC-010 is an open-label, single arm, externally controlled trial to evaluate safety, efficacy, pharmacodynamics and immunogenicity of AGIL-AADC in children from 18 months to less than 18 years of age with severe AADC deficiency, while NTUH-AADC-011 is an open- label, single arm, externally controlled trial to evaluate efficacy and safety of AGIL-AADC in children from 18 months to less than 6 years of age with severe AADC deficiency. In addition, sections 4.5, 4.9 and 6.6 of the SmPC are updated in order to provide better clarification and guidance for the medical practice. The Package Leaflet is updated accordingly. The MAH also took the opportunity to update the due date of the final report of study AADC-1602 in the Annex II to 2032, considering the 10-year follow up of the last patient in study AADC- 011, and to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/01/2024   | 11/03/2024 | SmPC, Annex II and PL | Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update information on safety and efficacy, based on final results from studies NTUH-AADC-010 and NTUH- AADC-011. Sections 4.5, 4.9 and 6.6 of the SmPC are updated in order to provide better clarification and guidance for the medical practice. |

<div style=\"page-break-after: always\"></div>

|                     | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                   |            |            |          |                                                                                                                                                                                                                                                                  |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0017              | 1st annual re-assessment                                                                                                                                                                                                                                                                       | 22/02/2024 | n/a        |          | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Upstaza should be maintained. |
| II/0013             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 22/02/2024 | 12/02/2025 | Annex II |                                                                                                                                                                                                                                                                  |
| PSUSA/11004 /202306 | Periodic Safety Update EU Single assessment - eladocagene exuparvovec                                                                                                                                                                                                                          | 11/01/2024 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| IB/0019             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                   | 13/11/2023 | n/a        |          |                                                                                                                                                                                                                                                                  |
| IB/0018             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                            | 24/10/2023 | n/a        |          |                                                                                                                                                                                                                                                                  |
| PSUSA/11004 /202212 | Periodic Safety Update EU Single assessment - eladocagene exuparvovec                                                                                                                                                                                                                          | 06/07/2023 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IB/0012   | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                | 08/06/2023   | 04/10/2023   | SmPC     |                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------|-------------------|
| IB/0010   | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                | 24/05/2023   | n/a          |          |                   |
| IB/0011   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                             | 08/05/2023   | n/a          |          |                   |
| IB/0009   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                      | 04/04/2023   | 04/10/2023   | Annex II |                   |
| IB/0007/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol A.6 - Administrative change - Change in ATC | 21/03/2023   | 04/10/2023   | SmPC     | Code/ATC Vet Code |
| II/0005/G | This was an application for a group of variations. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the                                                                                          | 23/02/2023   | n/a          |          |                   |

<div style=\"page-break-after: always\"></div>

|           | specifications limits range for the AS - Change in the specification parameters limits of the finished product - Change the approved specifications limits range                                                                                                                                                                                                                                                                                                                                                                                   |            |            |      | approved B.II.d.1.e and/or outside   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------|
| II/0004/G | This was an application for a group of variations. B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method using a biological reagent for a | 23/02/2023 | n/a        |      | method or a biological AS            |
| IB/0003   | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                              | 09/12/2022 | n/a        |      |                                      |
| IB/0001/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved protocol                                                                                                                                                                                                                                                                                                                       | 29/09/2022 | 04/10/2023 | SmPC | stability                            |

<div style=\"page-break-after: always\"></div>

|        | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                          |            |            |    |
|--------|--------------------------------------------------------------------------------------------------|------------|------------|----|
| N/0002 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/09/2022 | 04/10/2023 | PL |